Search

Displaying results 921 - 930 of 7674 in total
  1. Drug

    Benzatropine

    go.drugbank.com/drugs/DB00245
    ApprovedInvestigational

    [A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500] … The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased

  2. Drug

    Metoclopramide

    go.drugbank.com/drugs/DB01233
    ApprovedInvestigational

    It is available in the oral tablet form or in solution, and can also be administered through the intravenous route.[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922] … It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures.

    Categories: Dopamine D2 Receptor AntagonistsProducts: Nu-metoclopramide-tab 5mg, Nu-metoclopramide-tab 10mg
  3. Drug

    Tiapride

    go.drugbank.com/drugs/DB13025
    Investigational

    Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.

    Categories: Dopamine D2 Receptor Antagonists
  4. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    [A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. … [A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling

  5. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener. … When extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin.

  6. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved

  7. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention … Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans.

  8. Drug

    Sodium acetate

    go.drugbank.com/drugs/DB09395
    ApprovedInvestigational

    It can be used also in metabolic acidosis and for urine alkalinization. … Medically, sodium acetate is important component as an electrolyte replenisher when given intravenously. It is mainly indicated to correct sodium levels in hyponatremic patients.

    Mixtures: D-12043 Sol Conc Electrolyt Pour Dialy, INYECCION MULTIPLE DE ELECTROLITOS TIPO ISynonyms: Acetato de sodio
  9. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    [L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]

    Products: Nu-gemfibrozil Cap 300mg, Nu-gemfibrozil Tab 600mg
  10. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986] … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment